-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MeoZ6izHamVz200nMlKTM5IP2uVqBoNFEiIWsbQHE7sbUJL+jmNo4v97bGHV6RI2
 iFOnEU6hTo+VBUxJXbILGg==

<SEC-DOCUMENT>0001102624-09-000504.txt : 20091104
<SEC-HEADER>0001102624-09-000504.hdr.sgml : 20091104
<ACCEPTANCE-DATETIME>20091104103459
ACCESSION NUMBER:		0001102624-09-000504
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20091104
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20091104
DATE AS OF CHANGE:		20091104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		091156584

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: November  04, 2009</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>207-878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On November 4, 2009 ImmuCell Corporation (the "Company") issued a press release announcing financial results for the three-month and nine-periods ended September 30, 2009.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br />
<br>

<p>
<b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated November  04, 2009</a></b>
<br>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table border="0" width="100%">
<tr>
<td width="50%" valign=top>
Dated: November  04, 2009<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated November  04, 2009</td>
</tr>
</table>
</center>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Third Quarter of 2009</b>
<p>PORTLAND, ME -- (Marketwire - November  04, 2009) -  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the quarter and nine months
ended September 30, 2009.
</p>
<p>
For the three-month period ended September 30, 2009, product sales
increased by 9%, or $87,000, to $1,011,000 in comparison to the same period
in 2008.  For the nine-month period ended September 30, 2009, product sales
increased by 3%, or $91,000, to $3,472,000 in comparison to the same period
in 2008.
</p>
<p>
"During the third quarter, we reached a major milestone with the positive
results from the pivotal effectiveness study of Mast Out&#174;, while
maintaining reasonable sales of First Defense&#174; in this difficult dairy
economy with very low milk prices," commented Michael F. Brigham, President
and CEO.  "We are very pleased with these significant accomplishments and
positive results."
</p>
<p>
Product development expenses decreased by 32%, or $157,000, to $328,000
during the three-month period ended September 30, 2009 in comparison to the
same period in 2008.  Product development expenses increased by less than
1%, or $9,000, to $1,250,000 during the nine-month period ended September
30, 2009 in comparison to the same period in 2008.
</p>
<p>
The loss before income taxes was $(20,000) during the three-month period
ended September 30, 2009 in comparison to a loss before income taxes of
$(500,000) during the same period in 2008.   The net loss was $(19,000), or
$(0.01) per share, during the three-month period ended September 30, 2009
in comparison to a net loss of $(268,000), or $(0.09) per share, during the
same period in 2008.
</p>
<p>
The loss before income taxes was $(339,000) during the nine-month period
ended September 30, 2009 in comparison to a loss before income taxes of
$(710,000) during the same period in 2008.  The net loss was $(201,000), or
$(0.07) per share, during the nine-month period ended September 30, 2009 in
comparison to a net loss of $(429,000), or $(0.15) per share, during the
same period in 2008.
</p>
<p>
"Our product development spending and our loss before income taxes largely
reflect our strategic decision to make a significant and controlled
investment in Mast Out&#174;," added Mr. Brigham.  "On September 30, 2009, we
announced the results of the pivotal effectiveness study in approximately
300 qualified cows with subclinical mastitis that was conducted at sixteen
sites across the United States.  The Mast Out&#174; treatment group showed a
statistically highly significant (p &lt; 0.0001) overall cure rate in
comparison to the placebo group."
</p>
<p>
Cash, cash equivalents and short-term investments decreased by 2%, or
$110,000, to $4,944,000 at September 30, 2009 as compared to $5,054,000 at
December 31, 2008.  Stockholders' equity decreased by less than 1%, or
$25,000, to $9,619,000 at September 30, 2009 as compared to $9,644,000 at
December 31, 2008.  The Company had 2,971,000 shares of common stock
outstanding as of September 30, 2009.
</p>
<p>
<pre>
                                    (Unaudited)           (Unaudited)
                                 Three Months Ended    Nine Months Ended
                                    September 30,         September 30,
                                --------------------  --------------------
(In thousands, except per share
 amounts)                         2009       2008       2009       2008
                                ---------  ---------  ---------  ---------
Revenues:
Product Sales                   $   1,011  $     924  $   3,472  $   3,381
Other Revenues                          1         --          3          5
                                ---------  ---------  ---------  ---------
Total Revenues                      1,012        924      3,475      3,386

Cost and expenses:
Product costs                         412        621      1,665      1,882
Product development expenses          328        485      1,250      1,241
Selling, general and
 administrative expenses              311        368        987      1,139
                                ---------  ---------  ---------  ---------
Total costs and expenses            1,051      1,474      3,902      4,262
                                ---------  ---------  ---------  ---------

Net operating loss                    (39)      (550)      (427)      (876)

Interest and other income              19         50         88        166
                                ---------  ---------  ---------  ---------

Loss before income taxes              (20)      (500)      (339)      (710)
Income tax benefit                     (1)      (232)      (138)      (281)
                                ---------  ---------  ---------  ---------
Net loss                        $     (19) $    (268) $    (201) $    (429)
                                =========  =========  =========  =========

Net loss per common share:
Basic                           $   (0.01) $   (0.09) $   (0.07) $   (0.15)
Diluted                         $   (0.01) $   (0.09) $   (0.07) $   (0.15)
                                =========  =========  =========  =========

Weighted average common shares
 outstanding:
Basic                               2,971      2,895      2,955      2,893
Diluted                             2,971      2,895      2,955      2,893

(In thousands)                  At September 30, 2009 At December 31, 2008
                                --------------------- --------------------
Cash, cash equivalents and
 short-term investments               $  4,944              $  5,054
Total assets                             9,894                10,128
Net working capital                      6,094                 6,245
Stockholders' equity                  $  9,619              $  9,644
</pre>
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
